vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Lulu's Fashion Lounge Holdings, Inc. (LVLU). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $66.1M, roughly 1.3× Lulu's Fashion Lounge Holdings, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -11.8%). Lulu's Fashion Lounge Holdings, Inc. produced more free cash flow last quarter ($-2.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -14.7%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Lulu's Fashion Lounge Holdings, Inc. is a direct-to-consumer women's fashion retailer offering affordable, trendy apparel, footwear, and accessories. It primarily serves Gen Z and millennial consumers across North America, operating mainly via its e-commerce platform, with limited pop-up physical locations to boost customer engagement.
IOVA vs LVLU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $66.1M |
| Net Profit | — | $-31.9M |
| Gross Margin | 67.4% | 37.9% |
| Operating Margin | -84.7% | -52.8% |
| Net Margin | — | -48.2% |
| Revenue YoY | 17.7% | -11.8% |
| Net Profit YoY | — | -340.9% |
| EPS (diluted) | — | $-13.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | — | ||
| Q3 25 | $67.5M | — | ||
| Q2 25 | $60.0M | — | ||
| Q1 25 | $49.3M | — | ||
| Q4 24 | $73.7M | $66.1M | ||
| Q3 24 | $58.6M | $80.5M | ||
| Q2 24 | $31.1M | $92.0M | ||
| Q1 24 | $715.0K | $77.3M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | — | ||
| Q2 25 | $-111.7M | — | ||
| Q1 25 | $-116.2M | — | ||
| Q4 24 | — | $-31.9M | ||
| Q3 24 | $-83.5M | $-6.9M | ||
| Q2 24 | $-97.1M | $-10.8M | ||
| Q1 24 | $-113.0M | $-5.7M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | 37.9% | ||
| Q3 24 | 46.2% | 38.1% | ||
| Q2 24 | -0.8% | 45.5% | ||
| Q1 24 | — | 42.3% |
| Q4 25 | -84.7% | — | ||
| Q3 25 | -140.7% | — | ||
| Q2 25 | -189.8% | — | ||
| Q1 25 | -245.8% | — | ||
| Q4 24 | -117.5% | -52.8% | ||
| Q3 24 | -152.1% | -8.5% | ||
| Q2 24 | -327.6% | -4.9% | ||
| Q1 24 | -16464.6% | -8.0% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | — | ||
| Q2 25 | -186.2% | — | ||
| Q1 25 | -235.5% | — | ||
| Q4 24 | — | -48.2% | ||
| Q3 24 | -142.7% | -8.5% | ||
| Q2 24 | -312.2% | -11.7% | ||
| Q1 24 | -15800.8% | -7.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | $-13.46 | ||
| Q3 24 | $-0.28 | $-2.47 | ||
| Q2 24 | $-0.34 | $-3.92 | ||
| Q1 24 | $-0.42 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $4.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $13.4M |
| Total Assets | $913.2M | $108.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | — | ||
| Q3 25 | $300.8M | — | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | $4.5M | ||
| Q3 24 | $397.5M | $6.3M | ||
| Q2 24 | $412.5M | $1.8M | ||
| Q1 24 | $356.2M | $5.5M |
| Q4 25 | $698.6M | — | ||
| Q3 25 | $702.3M | — | ||
| Q2 25 | $698.5M | — | ||
| Q1 25 | $767.9M | — | ||
| Q4 24 | $710.4M | $13.4M | ||
| Q3 24 | $773.5M | $43.8M | ||
| Q2 24 | $768.5M | $48.7M | ||
| Q1 24 | $680.0M | $57.7M |
| Q4 25 | $913.2M | — | ||
| Q3 25 | $904.9M | — | ||
| Q2 25 | $907.4M | — | ||
| Q1 25 | $966.7M | — | ||
| Q4 24 | $910.4M | $108.2M | ||
| Q3 24 | $991.1M | $153.5M | ||
| Q2 24 | $964.3M | $145.3M | ||
| Q1 24 | $869.8M | $160.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-2.5M |
| Free Cash FlowOCF − Capex | $-61.9M | $-2.6M |
| FCF MarginFCF / Revenue | -71.3% | -3.9% |
| Capex IntensityCapex / Revenue | 10.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $1.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | — | ||
| Q3 25 | $-78.7M | — | ||
| Q2 25 | $-67.4M | — | ||
| Q1 25 | $-103.7M | — | ||
| Q4 24 | $-73.3M | $-2.5M | ||
| Q3 24 | $-59.0M | $-5.5M | ||
| Q2 24 | $-98.4M | $3.7M | ||
| Q1 24 | $-122.3M | $6.9M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | $-2.6M | ||
| Q3 24 | $-61.3M | $-5.9M | ||
| Q2 24 | $-98.9M | $3.4M | ||
| Q1 24 | $-126.5M | $6.4M |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | -3.9% | ||
| Q3 24 | -104.6% | -7.3% | ||
| Q2 24 | -317.9% | 3.7% | ||
| Q1 24 | -17685.3% | 8.3% |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | 0.0% | ||
| Q3 24 | 3.9% | 0.5% | ||
| Q2 24 | 1.4% | 0.4% | ||
| Q1 24 | 583.4% | 0.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LVLU
| Single Reportable Segment | $63.0M | 95% |
| Other | $2.4M | 4% |
| Stored Value Cards | $750.0K | 1% |
